Caverject (alprostadil)
Alprostadil Intracavernosal Kit; Intracavernosal Syringe (Ea); Intracavernosal Vial (Ea)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Alprostadil, the naturally occurring prostaglandin E1, is a vasodilating agent and a platelet-aggregation inhibitor.
Alprostadil, the naturally occurring prostaglandin E1, is a vasodilating agent and a platelet-aggregation inhibitor and is prepared synthetically for commercial use. Parenteral alprostadil is commercially available as a sterile powder for injection with (Caverject(R) Impulse(R)) or without alfadex (alpha-cyclodextrin) (Caverject(R)), as an alcoholic solution (Prostin VR Pediatric(R)), and as a lyophilized powder with alfadex (Edex(R)). The inclusion complex enhances the water solubility of alprostadil.
Alprostadil also is available as a urethral (micro) suppository, measuring 1.4 mm in diameter and 3 or 6 mm in length (Muse(R)). Prostaglandins of the E series occur naturally in the seminal vesicles and cavernous tissues of males and in the placenta and ductus arteriosus of the fetus. Alprostadil relaxes the smooth muscles of the corpus cavernosum and the ductus arteriosus.
Alprostadil is absorbed through the urethral mucosa and then distributed to corpus spongiosum and corpus cavernosum when administered as a urethral suppository.
USES: This medication is used to treat male sexual function problems (erectile dysfunction). It works by helping the blood flow into the penis to achieve and maintain an erection. This medication is not for use in women or children.
This medication is not recommended for use in men with penile implants. This medication does not protect against sexually transmitted diseases (such as HIV, hepatitis B, gonorrhea, syphilis). Using an effective barrier method (latex or polyurethane condom/dental dams) during sexual activity will help to decrease your risk of infection.
Generic name: alprostadil
Pronunciation: (al-PROS-ta-dil)
Drug class: Alprostadil
Therapeutic class: Drugs to treat Erectile Dysfunction
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Caverject
Indications
The following indications are listed for Caverject:
- Erectile Dysfunction
Also known as: Impotency.
Dosing
No dosing information is available for this tab.
Alprostadil is administered by intracavernosal injection for the treatment and diagnosis of erectile dysfunction, by urethral suppository for the treatment of erectile dysfunction, or by continuous IV or intra-arterial infusion to maintain the patency of the ductus arteriosus in neonates.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Caverject 20 Mcg Vial | Maintenance | Inject 1 milliliter (20 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse. |
| Caverject Impulse 10 Mcg Kit | Maintenance | Inject 10 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse. |
| Caverject Impulse 10 Mcg Syrng | Maintenance | Inject 10 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse. |
| Caverject Impulse 20 Mcg Kit | Maintenance | Inject 20 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse. |
| Caverject Impulse 20 Mcg Syrng | Maintenance | Inject 20 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse. |
| Caverject 40 Mcg Vial | Maintenance | Inject 1 milliliter (40 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse. |
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
- Deformity of erection of the penis
- Fibrosis of corpus cavernosum
- Leukemia
- Lymphoid leukemia
- Multiple myeloma
- Penile angulation
- Peyronie's disease
- Sickle cell disease
- Sickle cell trait
- Increased risk of bleeding due to coagulation disorder
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
Less Frequent
- Fibrosis of corpus cavernosum
- Infection
- Priapism
Rare or Very Rare
- Hypotension
- Peyronie's disease
- Supraventricular premature beats
- Testicular swelling
More Frequent
- Injection site sequelae
- Pain in penis
- Painful erection
Less Frequent
- Back pain
- Dizziness
- Ecchymosis
- Edema of penis
- Flu-like symptoms
- Headache disorder
- Hemorrhage
- Hyperhidrosis
- Hypertension
- Injection site inflammation
- Leg pain
- Penile angulation
- Penile hematoma
- Prostatitis
- Sinusitis
- Skin rash
- Upper respiratory infection
Rare or Very Rare
- Disorder of ejaculation
- Hematospermia
- Increased urinary frequency
- Pelvic pain
- Pruritus of skin
- Testicular pain
- Vasodilation of blood vessels
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Erectile dysfunction | ||
| F52.21 | ICD10CM | Male erectile disorder |
| N52 | ICD10CM | Male erectile dysfunction |
| N52.0 | ICD10CM | Vasculogenic erectile dysfunction |
| N52.01 | ICD10CM | Erectile dysfunction due to arterial insufficiency |
| N52.02 | ICD10CM | Corporo-venous occlusive erectile dysfunction |
| N52.03 | ICD10CM | Combined arterial insufficiency and corporo-venous occlusive erectile dysfunction |
| N52.1 | ICD10CM | Erectile dysfunction due to diseases classified elsewhere |
| N52.2 | ICD10CM | Drug-induced erectile dysfunction |
| N52.3 | ICD10CM | Postprocedural erectile dysfunction |
| N52.31 | ICD10CM | Erectile dysfunction following radical prostatectomy |
| N52.32 | ICD10CM | Erectile dysfunction following radical cystectomy |
| N52.33 | ICD10CM | Erectile dysfunction following urethral surgery |
| N52.34 | ICD10CM | Erectile dysfunction following simple prostatectomy |
| N52.35 | ICD10CM | Erectile dysfunction following radiation therapy |
| N52.36 | ICD10CM | Erectile dysfunction following interstitial seed therapy |
| N52.37 | ICD10CM | Erectile dysfunction following prostate ablative therapy |
| N52.39 | ICD10CM | Other and unspecified postprocedural erectile dysfunction |
| N52.8 | ICD10CM | Other male erectile dysfunction |
| N52.9 | ICD10CM | Male erectile dysfunction, unspecified |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.